Article section
An Evaluation of the Economic Burden of Chronic Diseases in Nigeria
Abstract
This study investigates the economic burden of chronic diseases in Nigeria, focusing on diabetes, cardiovascular diseases, and cancer. Using a quantitative approach, the analysis estimates direct and indirect costs, identifies contributing factors, and explores potential interventions. Findings reveal a substantial economic burden, with direct costs totaling $45 billion and indirect costs exceeding $100 billion annually. Healthcare utilization, disease prevalence, and lifestyle behaviors are significant drivers of costs. Policy interventions, including prevention programs, improved access to healthcare, and targeted interventions for vulnerable populations, are essential to mitigate the economic impact of chronic diseases in the developing world.
Keywords:
Chronic Diseases Cost-Benefit Cost-Effectiveness Economic Burden Healthcare
Article information
Journal
Journal of Medical Science, Biology, and Chemistry
Volume (Issue)
2(1), (2025)
Pages
75-83
Published
Copyright
Copyright (c) 2025 Yusuf Adeniyi Jamiu, Hauwa Victoria Ibrahim, Gogo Helen Kolo, Olalere Victoria Mayowa (Author)
Open access

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Abegunde, D. O., Mathers, C. D., Adam, T., Ortegon, M., & Strong, K. (2007). The burden and costs of chronic diseases in low-income and middle-income countries. The Lancet, 370(9603), 1929-1938. https://doi.org/10.1016/S0140-6736(07)61696-1.
Alzehr, A., Hulme, C., Spencer, A., & Morgan-Trimmer, S. (2022). The economic impact of cancer diagnosis to individuals and their families: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 30(8), 6385–6404. https://doi.org/10.1007/s00520-022-06913-x.
Alzubaidi, H., Sulieman, H., Mc Namara, K., Samorinha, C., & Browning, C. (2022). The relationship between diabetes distress, medication taking, glycaemic control and self-management. International Journal of Clinical Pharmacy, 44(1), 127-137. https://doi.org/10.1007/s11096-021-01322-2
Andersson, E., Persson, S., Hallén, N., Ericsson, Å., Thielke, D., Lindgren, P., ... & Jendle, J. (2020). Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden. Diabetologia, 63, 2582-2594. https://doi.org/10.1007/s00125-020-05277-3
Bahari, N. I., Ahmad, N., Mahmud, M. H., Baharom, M., Amir, S. M., Peng, C. S., ... & Nawi, A. M. (2023). Issues and challenges in the primary prevention of type 2 diabetes mellitus: A systematic review. Journal of Prevention, 44(1), 105-125. https://doi.org/10.1007/s10935-022-00707-x
Bloom, D. E., Chisholm, D., Jané-Llopis, E., Prettner, K., Stein, A., & Feigl, A. B. (2020). The global economic burden of noncommunicable diseases. Geneva: World Economic Forum.
Butt, M. D., Ong, S. C., Rafiq, A., Kalam, M. N., Sajjad, A., Abdullah, M., Malik, T., Yaseen, F., & Babar, Z. U. (2024). A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries. Journal of pharmaceutical policy and practice, 17(1), 2322107. https://doi.org/10.1080/20523211.2024.2322107
Bloom, D. E., Chen, S., Kuhn, M., McGovern, M. E., Oxley, L., & Prettner, K. (2020). The economic burden of chronic diseases: estimates and projections for China, Japan, and South Korea. The Journal of the Economics of Ageing, 17, 100163. https://doi.org/10.1016/j.jeoa.2018.09.002.
Gakidou, E., Afshin, A., Abajobir, A. A., Abate, K. H., Abbafati, C., & Abbas, K. M. (2020). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1345-1422.
Grabowski, D. C., Kansal, A. R., Goldman, D. P., & Lakdawalla, D. N. (2023). Assessment of Medical and Public Assistance Expenditures and Employment Among US Adults With Cancer Diagnoses. JAMA Network Open, 6(5), e2315823-e2315823. https://doi.org/doi:10.1001/jamanetworkopen.2023.15823
Grossman, M. (1972). On the Concept of Health Capital and the Demand for Health. The Journal of Political Economy, 80(2), 223-255.
Gallardo-Rincón, H., Cantoral, A., Arrieta, A., Espinal, C., Magnus, M. H., Palacios, C., & Tapia-Conyer, R. (2021). Type 2 diabetes in Latin America and the Caribbean: Regional and country comparison on prevalence, trends, costs and expanded prevention. Primary Care Diabetes, 15(2), 352-359. https://doi.org/10.1016/j.pcd.2020.10.001.
Johnson, R. W., Favreault, M. M., Dey, J., Marton, W., & Anderson, L. (2021). Risk of economic hardship among older adults issue brief. Risk, 2(01). https://aspe.hhs.gov/reports/risk-economic-hardship-among-older-adults-issue-brief-0
Kankeu, H. T., & Ventelou, B. (2019). Socioeconomic inequalities in informal payments for healthcare: An assessment of the ‘Robin Hood’ hypothesis in 33 African countries. Social Science & Medicine, 151, 173-186.
Macias-Konstantopoulos, W. L., Collins, K. A., Diaz, R., Duber, H. C., Edwards, C. D., Hsu, A. P., ... & Sachs, C. J. (2023). Race, healthcare, and health disparities: a critical review and recommendations for advancing health equity. Western journal of emergency medicine, 24(5), 906. https://doi.org/10.5811/westjem.58408
McMaughan, D. J., Oloruntoba, O., & Smith, M. L. (2020). Socioeconomic status and access to healthcare: interrelated drivers for healthy aging. Frontiers in public health, 8, 231.https://doi.org/10.3389/fpubh.2020.00231
O’Connell, J. M., & Manson, S. M. (2019). Understanding the Economic Costs of Diabetes and Prediabetes and What We May Learn About Reducing the Health and Economic Burden of These Conditions. Diabetes care, 42(9), 1609–1611. https://doi.org/10.2337/dci19-0017
Parker, E. D., Lin, J., Mahoney, T., Ume, N., Yang, G., Gabbay, R. A., ... & Bannuru, R. R. (2024). Economic costs of diabetes in the US in 2022. Diabetes care, 47(1), 26-43. https://doi.org/10.2337/dci23-0085
Rosendaal, N. T., Hendriks, M. E., Verhagen, M. D., Bolarinwa, O. A., Sanya, E. O., Kolo, P. M., Adenusi, P., Agbede, K., van Eck, D., Tan, S. S., Akande, T. M., Redekop, W., Schultsz, C., & Gomez, G. B. (2016). Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program. PloS one, 11(6), e0157925. https://doi.org/10.1371/journal.pone.0157925
Yusuf, S., Joseph, P., Rangarajan, S., Islam, S., Mente, A., Hystad, P., ... & Anand, S. S. (2020). Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. The Lancet, 395(10226), 795-808.